PV
Palvella Therapeutics, Inc.
PVLA · NASDAQ
$153.41 +0.32% (+$0.49)
1M +3.30%
Market Cap $2.20B
P/E Ratio -
Div. Yield -
ROE 47.84%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 10.15x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 23.89%
ROE 47.84%
ROA 24.34%
Debt
69 /100
Low Debt/Equity 0.00x
Current ratio 21.18x
Int. coverage -7.92x
Stability
19 /100
Unstable Beta -0.17x
EPS volatility 154.66%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PVLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Wesley H. Kaupinen
Employees
29
Headquarters
Wayne
Upcoming events
10 NOV
Earnings
Upcoming earnings report